250 related articles for article (PubMed ID: 30350563)
1. Identification of Novel Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors by Kinase Activity-Based High-Throughput Screening for Anticancer Therapeutics.
Zhang W; Hu X; Chakravarty H; Yang Z; Tam KY
ACS Comb Sci; 2018 Nov; 20(11):660-671. PubMed ID: 30350563
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel pyruvate dehydrogenase kinases inhibitors by screening of an in-house small molecule library for anti-lung cancer therapeutics.
Guo F; Zhao S; Li X
Bioorg Med Chem Lett; 2019 Jan; 29(2):291-296. PubMed ID: 30470491
[TBL] [Abstract][Full Text] [Related]
3. High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
Wu DM; Wang YJ; Fan SH; Zhang ZF; Shan Q; Lu J; Chen GQ; Zheng YL
Eur J Med Chem; 2019 Feb; 164():252-262. PubMed ID: 30597326
[TBL] [Abstract][Full Text] [Related]
4. Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
Fang A; Luo H; Liu L; Fan H; Zhou Y; Yao Y; Zhang Y
Bioorg Med Chem Lett; 2017 Dec; 27(24):5450-5453. PubMed ID: 29150396
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxicity screening to identify novel anti-osteosarcoma therapeutics targeting pyruvate dehydrogenase kinase 2.
Cao W; Wang Z; Han X; Liu J; Wang W
Bioorg Med Chem Lett; 2019 Oct; 29(20):126665. PubMed ID: 31495556
[TBL] [Abstract][Full Text] [Related]
6. Dichloroacetophenones targeting at pyruvate dehydrogenase kinase 1 with improved selectivity and antiproliferative activity: Synthesis and structure-activity relationships.
Zhang SL; Yang Z; Hu X; Tam KY
Bioorg Med Chem Lett; 2018 Nov; 28(21):3441-3445. PubMed ID: 30266541
[TBL] [Abstract][Full Text] [Related]
7. Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1.
Zhang SL; Yang Z; Hu X; Chakravarty H; Tam KY
Eur J Pharm Sci; 2018 Oct; 123():43-55. PubMed ID: 30012506
[TBL] [Abstract][Full Text] [Related]
8. Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect.
Zhang W; Zhang SL; Hu X; Tam KY
Eur J Pharm Sci; 2017 Dec; 110():93-100. PubMed ID: 28450154
[TBL] [Abstract][Full Text] [Related]
9. Rational design of mitochondria-targeted pyruvate dehydrogenase kinase 1 inhibitors with improved selectivity and antiproliferative activity.
Xu B; Yu Z; Xiang S; Li Y; Zhang SL; He Y
Eur J Med Chem; 2018 Jul; 155():275-284. PubMed ID: 29890389
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Yang Z; Zhang SL; Hu X; Tam KY
Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
[TBL] [Abstract][Full Text] [Related]
11. JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification.
Sun W; Xie Z; Liu Y; Zhao D; Wu Z; Zhang D; Lv H; Tang S; Jin N; Jiang H; Tan M; Ding J; Luo C; Li J; Huang M; Geng M
Cancer Res; 2015 Nov; 75(22):4923-36. PubMed ID: 26483203
[TBL] [Abstract][Full Text] [Related]
12. Ilimaquinone Induces the Apoptotic Cell Death of Cancer Cells by Reducing Pyruvate Dehydrogenase Kinase 1 Activity.
Kwak CH; Jin L; Han JH; Han CW; Kim E; Cho M; Chung TW; Bae SJ; Jang SB; Ha KT
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825675
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, crystal structures and anticancer activity of 4-substituted quinolines to target PDK1.
Vennila KN; Sunny D; Madhuri S; Ciattini S; Chelazzi L; Elango KP
Bioorg Chem; 2018 Dec; 81():184-190. PubMed ID: 30138906
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides as pyruvate dehydrogenase kinase 1 (PDK1) inhibitors to reduce the growth of cancer cells.
Zhang SL; Zhang W; Yang Z; Hu X; Tam KY
Eur J Pharm Sci; 2017 Dec; 110():87-92. PubMed ID: 28347773
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel 7-azaindoles as PDK1 inhibitors.
Wucherer-Plietker M; Merkul E; Müller TJJ; Esdar C; Knöchel T; Heinrich T; Buchstaller HP; Greiner H; Dorsch D; Finsinger D; Calderini M; Bruge D; Grädler U
Bioorg Med Chem Lett; 2016 Jul; 26(13):3073-3080. PubMed ID: 27217002
[TBL] [Abstract][Full Text] [Related]
16. Development of high-throughput TR-FRET and AlphaScreen assays for identification of potent inhibitors of PDK1.
Xu Z; Nagashima K; Sun D; Rush T; Northrup A; Andersen JN; Kariv I; Bobkova EV
J Biomol Screen; 2009 Dec; 14(10):1257-62. PubMed ID: 19822882
[TBL] [Abstract][Full Text] [Related]
17. Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation.
Mishra RK; Alokam R; Singhal SM; Srivathsav G; Sriram D; Kaushik-Basu N; Manvar D; Yogeeswari P
J Chem Inf Model; 2014 Oct; 54(10):2876-86. PubMed ID: 25254429
[TBL] [Abstract][Full Text] [Related]
18. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
Feldman RI; Wu JM; Polokoff MA; Kochanny MJ; Dinter H; Zhu D; Biroc SL; Alicke B; Bryant J; Yuan S; Buckman BO; Lentz D; Ferrer M; Whitlow M; Adler M; Finster S; Chang Z; Arnaiz DO
J Biol Chem; 2005 May; 280(20):19867-74. PubMed ID: 15772071
[TBL] [Abstract][Full Text] [Related]
19. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth.
Qin L; Tian Y; Yu Z; Shi D; Wang J; Zhang C; Peng R; Chen X; Liu C; Chen Y; Huang W; Deng W
Oncotarget; 2016 Jan; 7(2):1395-407. PubMed ID: 26593251
[TBL] [Abstract][Full Text] [Related]
20. Drug design and testing: profiling of antiproliferative agents for cancer therapy using a cell-based methyl-[3H]-thymidine incorporation assay.
Griffiths M; Sundaram H
Methods Mol Biol; 2011; 731():451-65. PubMed ID: 21516428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
